Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$205.87
+0.6%
$218.06
$193.03
$251.99
$59.10B0.351.73 million shs306,828 shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$433.46
-0.1%
$419.59
$356.14
$548.88
$35.16B1.5632,748 shs267,828 shs
Medtronic plc stock logo
MDT
Medtronic
$84.60
+0.7%
$88.08
$75.96
$96.25
$108.63B0.796.66 million shs1.32 million shs
Stryker Co. stock logo
SYK
Stryker
$368.26
+0.5%
$367.37
$314.93
$406.19
$140.54B0.931.35 million shs392,162 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-0.10%+4.18%-9.78%-17.88%-11.42%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-0.79%+6.72%+4.36%+3.86%-13.08%
Medtronic plc stock logo
MDT
Medtronic
-0.25%+2.60%-4.15%-8.84%+5.32%
Stryker Co. stock logo
SYK
Stryker
+0.34%+7.83%+0.60%-7.18%+9.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.8903 of 5 stars
3.53.04.24.03.53.31.3
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
4.4125 of 5 stars
3.43.00.03.73.52.51.3
Medtronic plc stock logo
MDT
Medtronic
4.5199 of 5 stars
3.23.03.34.03.41.70.6
Stryker Co. stock logo
SYK
Stryker
4.8232 of 5 stars
3.43.03.34.24.12.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
3.00
Buy$272.8632.54% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.78
Moderate Buy$523.7520.83% Upside
Medtronic plc stock logo
MDT
Medtronic
2.44
Hold$96.1413.65% Upside
Stryker Co. stock logo
SYK
Stryker
2.79
Moderate Buy$423.5315.01% Upside

Current Analyst Ratings Breakdown

Latest IDXX, SYK, MDT, and BDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $260.00
4/14/2025
Stryker Co. stock logo
SYK
Stryker
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$403.00
4/14/2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$450.00 ➝ $420.00
4/11/2025
Medtronic plc stock logo
MDT
Medtronic
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$93.00 ➝ $90.00
4/7/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$279.00 ➝ $261.00
3/21/2025
Stryker Co. stock logo
SYK
Stryker
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$442.00 ➝ $442.00
3/4/2025
Stryker Co. stock logo
SYK
Stryker
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$422.00
3/4/2025
Medtronic plc stock logo
MDT
Medtronic
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$92.00 ➝ $107.00
2/26/2025
Stryker Co. stock logo
SYK
Stryker
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$450.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00 ➝ $105.00
2/19/2025
Medtronic plc stock logo
MDT
Medtronic
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $95.00
(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.64B2.86$19.13 per share10.76$89.57 per share2.30
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.90B9.01$10.86 per share39.92$19.48 per share22.25
Medtronic plc stock logo
MDT
Medtronic
$33.20B3.27$6.93 per share12.21$38.69 per share2.19
Stryker Co. stock logo
SYK
Stryker
$22.60B6.22$14.37 per share25.62$54.08 per share6.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$6.0234.1913.161.638.47%15.74%7.29%5/1/2025 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.6740.6631.923.4122.78%55.82%26.48%5/1/2025 (Estimated)
Medtronic plc stock logo
MDT
Medtronic
$3.68B$3.2925.7414.512.2212.83%14.07%7.70%5/21/2025 (Estimated)
Stryker Co. stock logo
SYK
Stryker
$2.99B$7.7647.4524.832.9313.25%23.58%11.37%5/1/2025 (Estimated)

Latest IDXX, SYK, MDT, and BDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2025
Medtronic plc stock logo
MDT
Medtronic
$1.58N/AN/AN/A$8.81 billionN/A
5/1/2025Q2 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28N/AN/AN/A$5.35 billionN/A
5/1/2025Q1 2025
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$2.93N/AN/AN/A$998.25 millionN/A
5/1/2025Q1 2025
Stryker Co. stock logo
SYK
Stryker
$2.76N/AN/AN/A$5.68 billionN/A
2/18/2025Q3 2025
Medtronic plc stock logo
MDT
Medtronic
$1.36$1.39+$0.03$1.01$8.33 billion$8.29 billion
2/5/2025Q1 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.00$3.43+$0.43$1.04$5.13 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.02%+5.00%69.10%53 Years
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A
Medtronic plc stock logo
MDT
Medtronic
$2.803.31%+4.14%85.11%48 Years
Stryker Co. stock logo
SYK
Stryker
$3.360.91%+7.82%43.30%32 Years

Latest IDXX, SYK, MDT, and BDX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2025
Stryker Co. stock logo
SYK
Stryker
quarterly$0.840.86%3/31/20253/31/20254/30/2025
3/6/2025
Medtronic plc stock logo
MDT
Medtronic
quarterly$0.703%3/28/20253/28/20254/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.28
1.31
0.95
Medtronic plc stock logo
MDT
Medtronic
0.48
1.90
1.39
Stryker Co. stock logo
SYK
Stryker
0.59
1.95
1.32

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%
Medtronic plc stock logo
MDT
Medtronic
82.06%
Stryker Co. stock logo
SYK
Stryker
77.09%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.98%
Medtronic plc stock logo
MDT
Medtronic
0.20%
Stryker Co. stock logo
SYK
Stryker
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000287.14 million286.10 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
10,80081.04 million80.16 millionOptionable
Medtronic plc stock logo
MDT
Medtronic
95,0001.28 billion1.28 billionOptionable
Stryker Co. stock logo
SYK
Stryker
51,000381.69 million359.07 millionOptionable

Recent News About These Companies

Stryker (SYK) Projected to Post Earnings on Thursday
Stryker Co. stock logo
Stryker (SYK) to Release Earnings on Thursday
Stryker FFA assists county dive team

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$205.87 +1.24 (+0.61%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$433.46 -0.54 (-0.12%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Medtronic stock logo

Medtronic NYSE:MDT

$84.60 +0.56 (+0.66%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Stryker stock logo

Stryker NYSE:SYK

$368.26 +1.77 (+0.48%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.